Commerce & Finance Law Offices has a strong track record representing biotech and pharmaceutical companies on their listings, especially Chapter 18A listings in the Hong Kong market. Meng Zhang is experienced in private equity financing and M&A by foreign investors. Key individuals in the healthcare capital markets practice include Wei Sun, Xiaoman Zhang, and Bo Wang.
Legal 500 Editorial commentary
Key clients
- CICC
- UBS Huatai
- Laekna,Inc.
- Beijing Century Hong Shui Hospital Management Ltd.
- Sangon Biotech (Shanghai) Co.,Ltd.
- LBC Sunshine Healthcare Fund II L.P.
- Neusoft Xikang Holdings Inc.
- Concord Healthcare Group Co., Ltd.
- MedSci Healthcare Holdings Limited
- 3D Medicines (Shanghai) Co., Ltd
- China Life Private Equity Investment
- Shanghai Duoning Biotechnology Co., Ltd.
- Brise Pharmaceuticals (Beijing) Co., Ltd
- Gala Technology Holding Limited
- BioTrack Capital
- Lu DaoPei Medical Group Holding Limited
Work highlights
- Acted as PRC counsel to CICC as the sponsor and underwriter for Yaoshibang's Hong Kong listing.
- Advised UBS and Huatai as sponsors and underwriters for the listing of HighTide in Hong Kong.
- Acted as PRC legal advisor for Laekna Inc., assisting the sole sponsor in the IPO and listing on the Main Board of HKEx.